421 related articles for article (PubMed ID: 32228250)
1. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
4. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
5. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
Valencia-Sanchez C; Wingerchuk DM
BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for the treatment of neuromyelitis optica.
Duchow A; Chien C; Paul F; Bellmann-Strobl J
Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
[TBL] [Abstract][Full Text] [Related]
7. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
8. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
[TBL] [Abstract][Full Text] [Related]
9. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V; Flanagan EP
Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
[TBL] [Abstract][Full Text] [Related]
11. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
Stathopoulos P; Dalakas MC
Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
[TBL] [Abstract][Full Text] [Related]
12. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
[TBL] [Abstract][Full Text] [Related]
13. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
[TBL] [Abstract][Full Text] [Related]
14. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
15. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
[TBL] [Abstract][Full Text] [Related]
16. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
17. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
Illés Z
Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
[TBL] [Abstract][Full Text] [Related]
18. An update on biologic treatments for neuromyelitis optica spectrum disorder.
Kim W; Kim HJ
Expert Rev Clin Immunol; 2023 Jan; 19(1):111-121. PubMed ID: 36414430
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.
Tisavipat N; Juan HY; Chen JJ
Saudi J Ophthalmol; 2024; 38(1):2-12. PubMed ID: 38628414
[TBL] [Abstract][Full Text] [Related]
20. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
Mader S; Kümpfel T; Meinl E
Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
